bioAffinity Technologies, Inc ( BioAffinity Technologies)

Primary tabs

BioAffinity Technologies's picture

Management

Contact Address

About bioAffinity Technologies, Inc

bioAffinity Technologies, Inc. is a privately held development-stage company advancing proprietary early‐stage diagnostic technology applicable to a broad range of cancers.

BioAffinity Technologies press release, blog etc

Wed, 01/07/2026 - 16:51 bioAffinity Technologies Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
Thu, 12/04/2025 - 07:59 bioAffinity Technologies Noninvasive CyPath Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
Wed, 10/29/2025 - 22:50 bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
Sat, 10/18/2025 - 18:33 bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
Thu, 10/09/2025 - 17:45 bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Thu, 10/09/2025 - 17:39 bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Sat, 09/27/2025 - 08:10 bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath Lung
Fri, 09/05/2025 - 20:28 U.S. Medicine Magazine Spotlights CyPath Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
Sat, 08/16/2025 - 19:09 bioAffinity Technologies Reports Accelerating Growth in CyPath Lung Test Sales
Tue, 07/15/2025 - 18:08 bioAffinity Technologies Announces Notification of China Patent Award for Companys Noninvasive Lung Cancer Diagnostic
Sat, 06/14/2025 - 14:09 bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas Leadership Board
Fri, 05/23/2025 - 14:10 bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
Wed, 03/26/2025 - 17:34 Case Study: bioAffinity Technologies CyPath Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
Thu, 03/06/2025 - 20:51 bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath Lung Sales Growth
Wed, 01/22/2025 - 18:26 bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
Sun, 08/25/2024 - 09:50 bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
Wed, 08/14/2024 - 23:09 bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath Lung Sales
Wed, 06/12/2024 - 23:10 bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath Lung Tests
more

InfoBox

HomePagewww.bioaffinitytech.com